SCHEMBL25836666

SCHEMBL25836666

CC(C)(C)OC(=O)NCc1c[nH]cn1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.49
KDM4E B2RXH2 1/20 0.48
LMNA P02545 1/20 0.48
GFER P55789 2/20 0.43
CA12 O43570 2/20 0.42
CA1 P00915 2/20 0.42
CA2 P00918 2/20 0.42
CA9 Q16790 2/20 0.42
MAPT P10636 3/20 0.41
TDP1 Q9NUW8 3/20 0.41
NPSR1 Q6W5P4 2/20 0.41
RECQL P46063 1/20 0.41
KDM4A O75164 1/20 0.41
CACNA1H O95180 1/20 0.40
CACNA1B Q00975 1/20 0.40
CACNA1C Q13936 1/20 0.40
ALDH1A1 P00352 1/20 0.40
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
XBP1 P17861 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2083950 0.85 ALDH1A1 (0.50) L3MBTL1KDM4ELMNAGFERCA12
SCHEMBL19027837 0.82 TDP1 (0.48) L3MBTL1KDM4EGFERCA12CA1
Oxalic Acid SCHEMBL7506987 0.81 ALDH1A1 (0.47) L3MBTL1GFERCA12CA1CA2
SCHEMBL16133692 0.81 MAPT (0.40) L3MBTL1CA1CA2MAPTCACNA1B
SCHEMBL8649260 0.78 CA1 (0.45) L3MBTL1KDM4EGFERCA1CA2
SCHEMBL16136378 0.78 NPSR1 (0.50) KDM4EMAPTNPSR1ALDH1A1MEN1
SCHEMBL22455533 0.78 RAB9A (0.39) L3MBTL1KDM4EMAPTCACNA1HCACNA1B
SCHEMBL19100125 0.78 KDM4E (0.45) L3MBTL1KDM4ELMNAGFERCA12
SCHEMBL9515698 0.78 L3MBTL1 (0.36) L3MBTL1KDM4EMAPTTDP1ALDH1A1
SCHEMBL24306043 0.77 RIPK1 (0.33) MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3784669-B1 PTERIDINONE COMPOUNDS AND USES THEREOF VERTEX PHARMA (US) 2023-10-25 EP disclosed
US-20230287009-A1 OXO-SUBSTITUTED COMPOUND Sumitomo Pharma Co., Ltd. (JP) 2023-09-14 US disclosed
US-11702431-B2 Oxo-substituted compound Sumitomo Pharma Co., Ltd. (JP) 2023-07-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11702431-B2 Oxo-substituted compound CYP51A1, OXA1L, O60361 L3MBTL1 1189/4885KDM4E 2866/4885LMNA 1484/4885
US-20230287009-A1 OXO-SUBSTITUTED COMPOUND CYP51A1, OXA1L, O60361 L3MBTL1 1189/4885KDM4E 2866/4885LMNA 1484/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.